Eledon Pharmaceuticals (ELDN) Shares Outstanding (Weighted Average) (2013 - 2026)
Eledon Pharmaceuticals posted quarterly Shares Outstanding (Weighted Average) of $112.4 million for Q1 2026, up 45.77% year-on-year from $77.1 million in Q1 2025, and up 117.11% on a QoQ basis from $51.8 million in Q4 2025.
Eledon Pharmaceuticals (ELDN) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $112.4 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 45.77% year-over-year to $112.4 million; the trailing twelve-month figure through Mar 2026 stood at $112.4 million (up 45.77% YoY), and the FY2025 full-year result was $51.8 million, up 6.67% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $112.4 million, up from $51.8 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $112.4 million in Q1 2026 and bottomed at $14.3 million in Q2 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $30.0 million (2024), against an average of $42.1 million.
- The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) dropped 3.76%; it then soared 157.18% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $14.3 million in 2022, then jumped by 50.95% to $21.6 million in 2023, then soared by 125.11% to $48.5 million in 2024, then rose by 6.67% to $51.8 million in 2025, then jumped by 117.11% to $112.4 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $112.4 million (Q1 2026), $51.8 million (Q4 2025), and $77.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Eledon Pharmaceuticals | 419.90 Mn | 203.87 Mn | - | 112.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 112.42 Mn |
| Dec 31, 2025 | 51.78 Mn |
| Sep 30, 2025 | 77.16 Mn |
| Jun 30, 2025 | 77.16 Mn |
| Mar 31, 2025 | 77.13 Mn |
| Dec 31, 2024 | 48.54 Mn |
| Sep 30, 2024 | 51.95 Mn |
| Jun 30, 2024 | 42.28 Mn |
| Mar 31, 2024 | 29.99 Mn |
| Dec 31, 2023 | 21.56 Mn |
| Sep 30, 2023 | 29.97 Mn |
| Jun 30, 2023 | 24.01 Mn |
| Mar 31, 2023 | 14.29 Mn |
| Dec 31, 2022 | 14.29 Mn |
| Sep 30, 2022 | 14.27 Mn |
| Jun 30, 2022 | 14.27 Mn |
| Mar 31, 2022 | 14.33 Mn |
| Dec 31, 2021 | 14.82 Mn |
| Sep 30, 2021 | 14.82 Mn |
| Jun 30, 2021 | 14.82 Mn |
| Mar 31, 2021 | 14.83 Mn |
| Dec 31, 2020 | 1.45 Mn |
| Sep 30, 2020 | 1.11 Mn |
| Jun 30, 2020 | 943,419.00 |
| Mar 31, 2020 | 959,285.00 |
| Dec 31, 2019 | 655,526.00 |
| Sep 30, 2019 | 633,187.00 |
| Jun 30, 2019 | 10.60 Mn |
| Mar 31, 2019 | 9.43 Mn |
| Dec 31, 2018 | 9.01 Mn |
| Sep 30, 2018 | 9.42 Mn |
| Jun 30, 2018 | 8.58 Mn |
| Mar 31, 2018 | 7.75 Mn |
| Dec 31, 2017 | 4.68 Mn |
| Sep 30, 2017 | 6.94 Mn |
| Jun 30, 2017 | 2.27 Mn |
| Mar 31, 2017 | 413,635.00 |
| Dec 31, 2016 | 382,747.00 |
| Sep 30, 2016 | 81,339.00 |
| Jun 30, 2016 | 77,856.00 |
| Mar 31, 2016 | 22.63 Mn |
| Dec 31, 2015 | 22.48 Mn |
| Sep 30, 2015 | 22.54 Mn |
| Jun 30, 2015 | 22.42 Mn |
| Mar 31, 2015 | 22.38 Mn |
| Dec 31, 2014 | 6.47 Mn |
| Sep 30, 2014 | 1.12 Mn |
| Jun 30, 2014 | 501,133.00 |
| Mar 31, 2014 | 495,049.00 |
| Dec 31, 2013 | 416,037.00 |
| Sep 30, 2013 | 390,001.00 |